Brian Cherry Biography and Net Worth

Director of Atara Biotherapeutics

Brian Cherry has spent more than 25 years investing in and helping build businesses across a wide range of industries including healthcare, industrials, business services, financial services and consumer products. He has led buyout and growth equity investments in companies totaling over $25 billion in enterprise value. Previously, Mr. Cherry was a Managing Partner at Oak Hill Capital, a private equity firm. His board experience includes more than a dozen private and public companies, the U.S. Air Force Academy Foundation, and the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania.

Mr. Cherry earned his BA from Princeton University and his MBA from The Wharton School at the University of Pennsylvania.

What is Brian N. Cherry's net worth?: The estimated net worth of Brian N. Cherry is at least $1.54 million as of September 4th, 2026. Mr. Cherry owns 166,486 shares of Atara Biotherapeutics stock worth more than $1,539,996 as of September 15th. This net worth approximation does not reflect any other assets that Mr. Cherry may own. Learn More about Brian N. Cherry's net worth.
How do I contact Brian N. Cherry?: The corporate mailing address for Mr. Cherry and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on Brian N. Cherry's contact information.
Has Brian N. Cherry been buying or selling shares of Atara Biotherapeutics?: During the last quarter, Brian N. Cherry has bought $999,993.60 of Atara Biotherapeutics stock. Most recently, on Friday, September 4th, Brian N. Cherry bought 104,166 shares of Atara Biotherapeutics stock. The stock was acquired at an average cost of $9.60 per share, with a total value of $999,993.60. Following the completion of the transaction, the director now directly owns 166,486 shares of the company's stock, valued at $1,598,265.60. Learn More on Brian N. Cherry's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Brian Cherry (Director), Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Anhco Nguyen (President and Chief Executive Officer), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, Atara Biotherapeutics insiders bought shares 1 times. They purchased a total of 104,166 shares worth more than $999,993.60. During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 413,240 shares worth more than $3,851,596.86. The most recent insider tranaction occured on September, 4th when Director Brian N. Cherry bought 104,166 shares worth more than $999,993.60. Insiders at Atara Biotherapeutics own 41.2% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 9/4/2026.

Brian N. Cherry Insider Trading History at Atara Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/4/2026	Buy	104,166	$9.60	$999,993.60	166,486

Brian N. Cherry Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $9.32

$9.21

$9.37

50 Day Range

MA: $8.94

$7.71

$10.26

2 Week Range

Now: $9.32

$3.92

$19.15

Volume

2,570 shs

Average Volume

675,534 shs

Market Capitalization

$93.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1